Get the Stockscreener App
9.03
1.80%
0.16
Dbv Technologies Adr stock is traded at $9.03, with a volume of 268.63K.
It is up +1.80% in the last 24 hours and down -23.21% over the past month.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.
See More
Previous Close:
$8.87
Open:
$8.87
24h Volume:
268.63K
Relative Volume:
0.60
Market Cap:
$567.52M
Revenue:
$222.20K
Net Income/Loss:
$-168.02M
P/E Ratio:
-2.0015
EPS:
-4.5116
Net Cash Flow:
$-152.10M
1W Performance:
-5.45%
1M Performance:
-23.21%
6M Performance:
-57.51%
1Y Performance:
-43.28%
1-Day Range:
$8.85
$9.205
1-Week Range:
$8.86
$9.86
52-Week Range:
$8.85
$26.18
Dbv Technologies Adr Stock (DBVT) Company Profile
Name
Dbv Technologies Adr
Sector
Industry
Phone
33(0)155427878
Address
107 AVENUE DE LA REPUBLIQUE, CHATILLON
Compare DBVT vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DBVT
Dbv Technologies Adr
|
9.03 | 567.52M | 222.20K | -168.02M | -152.10M | -4.5116 |
VRTX
Vertex Pharmaceuticals Inc
|
508.43 | 128.87B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
237.56 | 94.84B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
800.54 | 82.42B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
849.87 | 53.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
371.60 | 42.04B | 5.76B | 514.49M | 1.10B | 4.4813 |
Dbv Technologies Adr Stock (DBVT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-15-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-03-25 | Initiated | Guggenheim | Buy |
| May-29-25 | Resumed | Goldman | Sell |
| Jan-04-23 | Upgrade | Societe Generale | Hold → Buy |
| Dec-16-22 | Downgrade | Goldman | Neutral → Sell |
| May-10-22 | Downgrade | Goldman | Buy → Neutral |
| Sep-14-21 | Upgrade | Societe Generale | Hold → Buy |
| Jan-22-21 | Downgrade | Societe Generale | Hold → Sell |
| Nov-02-20 | Upgrade | Societe Generale | Sell → Hold |
| Aug-06-20 | Downgrade | Societe Generale | Buy → Sell |
| Aug-05-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-17-20 | Downgrade | Stifel | Buy → Hold |
| Jan-09-20 | Upgrade | Stifel | Hold → Buy |
| Dec-16-19 | Initiated | Citigroup | Buy |
| Sep-05-19 | Resumed | Morgan Stanley | Equal-Weight |
| Jun-17-19 | Initiated | Goldman | Buy |
| Dec-20-18 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-20-18 | Downgrade | BofA/Merrill | Buy → Underperform |
| Dec-20-18 | Downgrade | Jefferies | Buy → Hold |
| Dec-20-18 | Downgrade | Stifel | Buy → Hold |
| Oct-31-17 | Upgrade | Societe Generale | Sell → Hold |
| Oct-24-17 | Downgrade | Societe Generale | Buy → Sell |
| Oct-23-17 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-23-17 | Initiated | Deutsche Bank | Buy |
| Mar-16-17 | Upgrade | Societe Generale | Hold → Buy |
| Sep-26-16 | Initiated | JMP Securities | Mkt Outperform |
| Dec-03-15 | Initiated | Barclays | Overweight |
| Oct-23-15 | Initiated | BofA/Merrill | Buy |
View All
Dbv Technologies Adr Stock (DBVT) Latest News
DBV Technologies Submits FDA Biologics License Application for VIASKIN Peanut Patch in Children Ages 4-7 - Kalkine Media
DBV Technologies annonce le dépôt de sa demande de licence biologique (BLA) auprès de la Food and Drug Administration des Etats-Unis pour le patch VIASKIN® Peanut destiné aux enfants âgés de 4 à 7 ans. - GlobeNewswire Inc.
DBV Technologies Announces Submission of Biologics License Application to U.S. FDA for the VIASKIN® Peanut Patch in Children Aged 4-7 Years - GlobeNewswire Inc.
DBVT Stock Price, Quote & News - Syfe
DBV Technologies S.A. (DBV.PA) Stock Price, News, Quote & History - Yahoo! Finance Canada
DBVT Slides As DBV Technologies Leads Biotech ADR Losers - StocksToTrade
DBVT Slides As DBV Technologies Leads European Biotech Declines - timothysykes.com
DBV Technologies (DBVT) Soars 5.3%: Is Further Upside Left in the Stock? - Eastern Progress
Zai Lab LimitedADR Peer Comparison – Compare with Others - valueresearchonline.com
DBV Technologies to Participate in Upcoming September Investor Conferences - GlobeNewswire
A food-allergy treatment company will join three New York events in September - Stock Titan
Mesoblast LimitedADR Peer Comparison – Compare with Others - Value Research
DBV Technologies (DBVT) Edges Higher as Allergy Franchise Holds Above Key SupportATR Stop - dars.gov.et
DBV Technologies (DBVT) Edges Higher as Allergy Franchise Holds Above Key SupportMutual Fund Flow - siam.in
DBV Technologies (DBVT) Edges Higher as Allergy Franchise Holds Above Key SupportChannel Breakout - www.dars.gov.et
DBV Technologies (DBVT) Edges Higher as Allergy Franchise Holds Above Key SupportMomentum Stock Picks - www.dars.gov.et
DBV (DBVT) Quarterly Scorecard: The Bottom-Line Figure Trails Its Comparison at the Close; Market Reaction: Shares Move 2.14% Higher in the Latest ReadingEarnings Surprise Score - careplusvn.com
DBV (DBVT) Quarterly Scorecard: The Bottom-Line Figure Trails Its Comparison at the Close; Market Reaction: Shares Move 2.14% Higher in the Latest ReadingEarnings Quality Score - dars.gov.et
DBV (DBVT) Quarterly Scorecard: The Bottom-Line Figure Trails Its Comparison at the Close; Market Reaction: Shares Move 2.14% Higher in the Latest ReadingEarnings Beat Alert - dars.gov.et
DBV Technologies (NASDAQ:DBVT) Shares Up 6.2%Here's Why - MarketBeat
European ADRs Started The Week Slightly Higher In US Trading - Finimize
DBVT Q2 2026 Earnings: Wider-than-Expected Loss Reflects Pipeline Investment PressuresPost-Earnings Drift - careplusvn.com
MPM BioImpact LLC discloses 6.2% stake in DBV Technologies (DBVT) - Stock Titan
DBV technologies S.A. (ADR) (DBV1.SG) balance sheet - Yahoo Finance UK
DBV Technologies (NASDAQ:DBVT) Stock Price Up 8.4%Time to Buy? - MarketBeat
RA Capital discloses DBV Technologies (DBVT) 5.8% ownership via ADS holding - Stock Titan
DBV Technologies Announces Sale of Approximately $50 Million of ADSs Through Its At-The-Market (ATM) Program on Nasdaq - The Manila Times
DBV Technologies Announces Sale of Approximately $50 - GlobeNewswire
Form S-3ASR DBV TECHNOLOGIES S.A. For: 27 July By Investing.com - Investing.com Canada
Form S-3ASR DBV TECHNOLOGIES S.A. For: 27 July By Investing.com - Investing.com Nigeria
Spyre Therapeutics (SYRE) Receives a Buy from Guggenheim - The Globe and Mail
Europe’s US-Listed ADRs Edged Higher Late Friday Morning - Finimize
DBV Technologies: Viaskin's FDA Path Still Leaves Room For More Upside (NASDAQ:DBVT) - Seeking Alpha
DBV Technologies on Track for Lowest Close Since December 2025 -- Data Talk - Moomoo
DBV Technologies stock falls on $150M share offering plan - Investing.com
DBV Technologies Files At-The-Market (ATM) Prospectus for Up to $150 Million of Sales - The Manila Times
DBV Technologies Files At-The-Market (ATM) Prospectus for Up to $150 Million of Sales - markets.businessinsider.com
DBV Technologies Files At-The-Market (ATM) Prospectus for Up to $150 Million of Sales - GlobeNewswire
DBV Technologies S.A. - Via Ritzau
Cantor Fitzgerald reiterates Overweight on DBV Technologies stock - investing.com
DBV Technologies Reports Second Quarter and Half-Year 2026 Financial Results and Business Update - markets.businessinsider.com
DBV Technologies narrows Q2 loss, funds operations into Q3 2027 - scanx.trade
DBV Technologies Announces the Filing of its 2026 Half-Year Report ― Conditions for Accessing or Consulting the Report - markets.businessinsider.com
DBV Technologies (NASDAQ: DBVT) sees $174.9M cash and Q3 2027 runway - Stock Titan
DBV Technologies Announces the Filing of its 2026 Half-Year - GlobeNewswire
DBV Technologies Reports Second Quarter and Half-Year 2026 Financial Results and Business Update - The Manila Times
DBV Technologies Reports Second Quarter and Half-Year 2026 Financial Results and Business Update - GlobeNewswire
Earnings call transcript: DBV Technologies slips on Q2 2026 update - investing.com
DBV Technologies to Report Second Quarter 2026 Financial Results and Business Update on July 16, 2026 - markets.businessinsider.com
DBV Technologies' July 16 webcast will cover Q2 results - Stock Titan
Dbv Technologies Adr Stock (DBVT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Dbv Technologies Adr Stock (DBVT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Mohideen Pharis | Chief Medical Officer |
Jan 29 '26 |
Sale |
4.86 |
534 |
2,595 |
144,995 |
| EPIC Bpifrance | Member of 10% owner group |
Dec 18 '25 |
Sale |
4.19 |
1,292,103 |
5,413,912 |
7,303,369 |
| EPIC Bpifrance | Member of 10% owner group |
Dec 17 '25 |
Sale |
4.85 |
2,076,990 |
10,070,232 |
8,595,472 |
| Mohideen Pharis | Chief Medical Officer |
Nov 21 '25 |
Sale |
2.77 |
1,624 |
4,498 |
101,529 |
| Mohideen Pharis | Chief Medical Officer |
Nov 20 '25 |
Sale |
2.88 |
6,496 |
18,708 |
103,153 |
3.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):